ExploreWatchlistsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Cash from financing

Oncolys BioPharma Inc. (4588)

Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndCash from financing (Million JPY)YoY (%)
Dec 31, 20253,222+11.89%
Dec 31, 20242,879+152.02%
Dec 31, 20231,143-1103.73%
Dec 31, 2022-114-103.68%
Dec 31, 20213,091+1176.06%
Dec 31, 2020242-78.43%
Dec 31, 20191,123-2.09%
Dec 31, 20181,147-22.30%
Dec 31, 20171,477+22887.75%
Dec 31, 20166-105.35%
Dec 31, 2015-120+51427.90%
Dec 31, 2014-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat